BIOA
BioAge Labs Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +6.7% ·
share flow +13.4% ·
net new positions +6.2%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 256 | $1,742 | n/a | n/a |
| Q2 2026 | 66 | +4 | 13.22M | $323.71M | +6 | −2 |
| Q1 2026 | 65 | +14 | 13.97M | $243.82M | +19 | −5 |
| Q4 2025 | 51 | +2 | 8.60M | $113.77M | +2 | n/a |
| Q3 2025 | 16 | +1 | 5.16M | $30.36M | +1 | n/a |
| Q2 2025 | 12 | +5 | 4.16M | $17.19M | +5 | n/a |
| Q1 2025 | 4 | 0 | 455.40K | $1.71M | +2 | −2 |
| Q4 2024 | 4 | -5 | 347.20K | $2.01M | +1 | −6 |
| Q3 2024 | 8 | +8 | 1.18M | $24.62M | +8 | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 1.65M | +6.0% | $9.71M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 2 | BlackRock ✦ (passive) | 1.28M | -0.6% | $7.52M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Geode Capital Management ✦ (passive) | 562.73K | +24.1% | $3.31M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 306.55K | +749.8% | $1.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Morgan Stanley ✦ | 228.16K | n/a | $1.34M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 6 | State Street Global Advisors ✦ (passive) | 198.11K | +23.2% | $1.16M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Marshall Wace ✦ | 174.20K | -23.2% | $1.02M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 143.00K | +60.1% | $840,840 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 114.06K | +4.1% | $670,690 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 10 | D. E. Shaw & Co. ✦ | 104.28K | +54.7% | $613,172 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 99.67K | +54.3% | $586,054 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Fidelity (FMR) ✦ | 91.12K | +17.5% | $535,774 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Goldman Sachs Group ✦ | 89.68K | n/a | $527,306 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | JPMorgan Chase ✦ | 73.70K | n/a | $433,332 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 15 | AQR Capital Management ✦ | 35.75K | +13.3% | $210,187 | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 16 | T. Rowe Price ✦ | 11.89K | New | $70,000 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| T. Rowe Price | $70,000 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 143 holders, 34.12M shares, $588.17M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.